Early capital into biotech rarely waits for a finished clinic trial. Allocators who move first still face clocks that differ sharply by city pair, and those clocks decide whether an incubator introduction becomes a term sheet or a polite pass. This piece walks through how those timelines actually behave for people who write the first checks, without assuming a science degree or a prior fund seat.
Why Biotech Diligence Moves Differently Across City Pairs
Biotech diligence is not a single calendar that every city shares. A Boston founder with wet-lab access and a ready scientific advisory board can clear scientific review faster than a peer in a secondary hub who still needs core facility time. Pair the first city with a second city that supplies capital or regulatory talent, and the combined schedule becomes a product of both places. Early investors who treat the pair as one market miss the hand-off points where months are gained or lost. Foundation teams track those hand-offs because people, not slide decks, set the real pace. That is why patterns described in Why We Invest in People Before They Have a Company keep appearing in biotech: the founder who already knows the next lab manager shortens every subsequent step.
Allocators also watch how capital density travels between the two cities. When one city holds the science and the other holds the later-stage funds, diligence can stall while the second city digests data packages. The reverse flow is faster when the second city already trusts the first city's incubators. City pairs therefore create two distinct clocks: an origin clock driven by lab and patent readiness, and a destination clock driven by check size and committee rhythm.
Mapping Boston-San Francisco Cycles Against London-Cambridge Windows
Boston and San Francisco form one of the most watched pairs for early biotech capital. Preclinical packages originating in Cambridge, Massachusetts, often reach Bay Area partners within eight to twelve weeks if the science is clean and the intellectual property is already filed. The same package moving from a London spin-out into the Cambridge, UK, orbit can take longer when hospital ethics boards or dual-listing questions intervene. Allocators who fly both routes keep separate calendars rather than a single global average. They note that San Francisco committees often front-load manufacturing questions, while Boston committees front-load target validation.
London-Cambridge pairs add a currency and regulatory overlay that Boston-San Francisco rarely faces. Early investors therefore budget an extra review cycle when sterling and Food and Drug Administration (FDA) expectations must both be satisfied. Public data from the OECD SME and entrepreneurship work helps frame how small research firms absorb those extra weeks. The lesson for allocators is simple: never import a Boston timeline into a London deal without adjusting for the second city's own gates.
How Early Allocators Clock Preclinical Review in Twin Hubs
Preclinical work is the first long stretch most early investors can influence. In twin-hub models the science city runs the assays while the capital city runs the model checks. A clean pair of cities can compress that stretch to roughly ninety days when both sides already share incubators and data rooms. When the cities are less familiar with each other, the same stretch expands past one hundred fifty days because every assay needs a second explanation. Allocators who map those twin hubs in advance know which introductions to force early and which to leave until the data stabilizes.
Unit economics literacy becomes useful even at this stage. Seed-stage biotech does not yet have product margins, yet it does have burn rates per assay and per full-time scientist. Comparing those rates across hubs is the same skill set outlined in Unit Economics Literacy in Seed Stage: Global Market Comparison. An allocator who sees a London burn twice that of a Boston peer will demand a tighter experimental plan before the diligence clock starts. That demand itself becomes part of the timeline.
Patent and Regulatory Clocks That Stretch or Compress Timelines
Intellectual property filings set a hard floor under many biotech timelines. Provisional applications filed at the US Patent and Trademark Office give a twelve-month window that forces founders and investors to decide whether to expand the family. When the science city and the capital city sit under different patent regimes, that window can feel shorter because translation and foreign filing decisions stack on top of the science review. Early investors who ignore the patent clock often discover the deal has aged out of their fund's preferred vintage.
Regulatory clocks interact with patent clocks. An early conversation with the FDA or the European Medicines Agency can de-risk a package, yet the meeting itself may require six to nine months of preparation. City pairs that already host frequent agency interactions compress that preparation; pairs that do not must add buffer. Allocators therefore treat patent and regulatory milestones as twin constraints rather than sequential boxes. The same discipline appears when defense-oriented life-science deals face export controls, a comparison explored in Defense Tech Investment Committees: Cross-Border Benchmarking Methods.
Capital Staging When One City Leads and the Partner Follows
Most early biotech rounds still stage capital. The lead city writes the first check and sets the diligence bar; the partner city joins later with a larger check and a lighter scientific re-review. That staging works only when the second city trusts the first city's process. When trust is low, the second city restarts key parts of the diligence and the total timeline doubles. Allocators who sit on both sides of a city pair therefore invest in shared language early: common data templates, shared scientific advisors, and clear ownership of which city owns which risk.
Securities rules also shape staging. Disclosures required by the US Securities and Exchange Commission for certain structures add calendar days that pure private rounds avoid. Early investors who plan to syndicate into public-market vehicles keep those extra days in the model from day one. The practical effect is that a city pair with strong private-market density can finish faster than a pair that must later satisfy public disclosure norms.
Reading Signals From Founder Density and Lab Access
Founder density is a quiet predictor of diligence speed. Cities that graduate many biotech founders every year also graduate shared norms about how much data is "enough" for a seed check. Lab access compounds that effect: when core facilities are oversubscribed, assay queues lengthen and the origin clock slows. Allocators who visit both cities in a pair can see the queues with their own eyes and adjust expectations before term sheets circulate. They also notice which incubators actively broker time on equipment versus which ones merely list it.
Macro signals help place those local observations in context. Reports gathered under World Bank innovation themes show how public research infrastructure affects private company velocity. Early investors who track both the street-level lab queues and the broader infrastructure data avoid over-weighting a single good meeting. They also keep an eye on reconstruction and new-market corridors such as the Ukraine reconstruction opportunity, where fresh lab capacity can suddenly alter city-pair economics for certain therapeutic areas.
What Allocators Compare When They Fly the Pair Routes
Travel between the two cities is itself part of the diligence. An allocator who can complete a science day in Boston and a capital day in San Francisco within seventy-two hours learns more than one who spreads the same meetings across three weeks of video calls. Face-to-face time compresses trust formation, especially when the science is still pre-print. Yet the value of those flights depends on preparation: knowing which questions each city is best positioned to answer. Science cities answer mechanism and data quality; capital cities answer follow-on appetite and syndicate composition.
Comparisons also extend to soft factors such as immigration rules for key hires and the availability of specialized counsel. A city pair that can move a senior scientist across the border in weeks will finish diligence faster than a pair that faces multi-month visa queues. Early investors record those soft factors in the same notebooks they use for assay results. Over time the notebooks become a private map that no public database fully replaces. Readers who want more of that practical map can browse the Investing In Tech archive for related city and sector notes.
Building a Personal Calendar From Public Authority Data
Public sources already publish enough raw material for an allocator to draft a first-pass calendar. Macroeconomic and fiscal publications from the IMF publications desk help size the capital available in each city of the pair. Patent office dashboards show filing volume and average pendency. Securities filings reveal how long recent biotech rounds took from first meeting to close. Combining those three streams gives a baseline that personal meetings can then refine. The baseline is never perfect, yet it prevents the common error of assuming every city pair runs on Silicon Valley time.
Foundation keeps the same sources open for any allocator who asks. The For Investors page points to program calendars and office hours where city-pair questions can be stress-tested with operating partners. Common process questions also appear in the FAQ (frequently asked questions), including how incubator introductions interact with formal diligence clocks. The goal is not to replace judgment but to give every early investor a shared starting map so that the first conversations with founders already sit inside a realistic window.
City-pair diligence will keep evolving as new hubs rise and existing ones densify. Allocators who treat timelines as living products of two places rather than fixed industry averages will keep their capital moving while the science is still young. That habit, more than any single model, separates the funds that catch the first wave from those that arrive after the second city has already priced the deal.
See also Ukraine reconstruction opportunity.
Related Foundation reading: Alumni Angel Network Operations: Architecture and Design Choices.
Timeless Value. Perpetual Legacy.
